SARM1

Asha Therapeutics Announces the Nomination of a Novel Intra-Molecular Glue Development Candidate ASHA-624 as a Disease Modifying Therapeutic for Amyotrophic Lateral Sclerosis

Retrieved on: 
Monday, April 1, 2024
Data Management, Other Health, Technology, Pharmaceutical, Oncology, General Health, Mental Health, Neurology, Clinical Trials, Other Technology, Biotechnology, Science, Software, Other Science, Research, Health, Conference, ALS, Disease, Patient, CNS, Amyotrophy, Asha, CIPN, Doctor of Philosophy, Tetraplegia, Safety, De novo, SARM1, Pharmaceutical industry

Asha Therapeutics (Asha) ( www.ashatherapeutics.com ), a life sciences company designing de novo disease modifying medicines for neurodegenerative diseases with high unmet medical need, announced today the nomination of a development candidate, ASHA-624 targeting SARM1 as a potential disease modifying therapy for Amyotrophic Lateral Sclerosis (ALS) with additional indications in Chemotherapy-Induced Peripheral Neuropathy (CIPN), Glaucoma, and traumatic brain and spinal cord injuries.

Key Points: 
  • Asha Therapeutics (Asha) ( www.ashatherapeutics.com ), a life sciences company designing de novo disease modifying medicines for neurodegenerative diseases with high unmet medical need, announced today the nomination of a development candidate, ASHA-624 targeting SARM1 as a potential disease modifying therapy for Amyotrophic Lateral Sclerosis (ALS) with additional indications in Chemotherapy-Induced Peripheral Neuropathy (CIPN), Glaucoma, and traumatic brain and spinal cord injuries.
  • Dr. Michael Gold, MD, MS, a member of Asha’s Scientific Advisory Board noted, “SARM-1 is a well-validated therapeutic target that could yield novel therapies for patients suffering from a range of both central and peripheral nervous disorders.
  • ASHA-624 prevents the activation of SARM-1 using a completely novel approach that has the potential to deliver a therapy with robust clinical efficacy and few, if any, off-target side effects.
  • We are committed through our work to the transformation of patient outcomes, and believe ASHA-624 is a significant step forward towards achieving that goal,” commented Dr. Heckmann, PhD.

Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746

Retrieved on: 
Friday, August 25, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Senior, Bio, AFL, Traumatic brain injury, Diffuse axonal injury, Pharmacokinetics, ALS, TBI, CIPN, Multiple sclerosis, Doctor of Philosophy, MS, SARM1, Amyotrophy, Safety, Pharmaceutical industry

Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation of the Phase 1 clinical trial of its SARM1 inhibitor, NB-4746.

Key Points: 
  • Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation of the Phase 1 clinical trial of its SARM1 inhibitor, NB-4746.
  • NB-4746 is believed to be a first-in-class, oral, brain-penetrant, neuroprotective SARM1 inhibitor with broad therapeutic potential across diseases of the central, peripheral, and ocular nervous systems.
  • “We are excited about the potential of NB-4746,” said David Lau, PhD, Senior Vice President, Development Sciences, Nura Bio.
  • “The initiation of the Phase 1 trial of NB-4746 marks Nura Bio’s transition to a clinical-stage company,” said Shilpa Sambashivan, PhD, Chief Scientific Officer, Nura Bio.

Worldwide SARM1 Inhibitors Industry to 2040 - Current and Future Market Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Pharmaceutical, Health, UN, Multiple sclerosis, Death, Sterile alpha motif, Neurodegeneration, Research, Alzheimer's disease, Neurological disorder, Amyotrophic lateral sclerosis, Publication, SARM1, ALS, Patient, Vance DeGeneres, Therapy, First Nations in Ontario, United Nations, Parkinson's disease, Fine chemical, Pharmaceutical industry, Distribution (marketing), Creative industries

This report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040.

Key Points: 
  • This report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040.
  • Neurological disorders are considered the second leading cause of death and the primary cause of long-term disability, worldwide.
  • What are the recent developments and strategic initiatives undertaken by players engaged in this market space related to research and development of SARM1 inhibitors therapeutics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

SARM1 Inhibitors Market by Target Indications, Type of Molecules, Drug Developers, Drug Candidates and Key Geographies : Industry Trends and Global Forecasts, 2022-2040

Retrieved on: 
Monday, December 12, 2022
Molecule, United Nations, Therapy, NIH, Peripheral neuropathy, Neurological disorder, COVID-19 drug development, Amyotrophic lateral sclerosis, Patient, Multiple sclerosis, Glaucoma, Research, Neurodegeneration, Death, Element, CPC, Alzheimer's disease, Geography, Investment, Parkinson's disease, Sterile alpha motif, Vance DeGeneres, Growth, UN, First Nations in Ontario, SARM1, Patent, Organization, Pharmaceutical industry, Fine chemical, Medical device

View original content:https://www.prnewswire.com/news-releases/sarm1-inhibitors-market-by-targ...

Key Points: 
  • In fact, the annual expenditure associated with neurological disorder care in 2020 was more than USD 655 billion, in the US alone.
  • Additionally, several patents related to SARM1 targeting therapies have been recently filed / granted, demonstrating the continued innovation in this domain.
  • Information on recent developments (partnerships and collaborations, and funding and investments) reported by several players engaged in the SARM1 targeting therapeutics domain.
  • This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments.

Nura Bio Reports Preclinical Data Validating a Conserved Mechanism of Inhibition of NAD Hydrolases Implicated in Neurodegeneration in Neuron

Retrieved on: 
Tuesday, September 13, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Lists of diseases, NAD, Hope, SARM1, Hydrolase, Hydrolysis, MS, Vance DeGeneres, Nura, Nerve injury, CD38, Biology, Bratkowski, TBI, Neuroprotection, Doctor of Philosophy, Diagnosis, ALS, Research, Neurological disorder, CIPN, Founding, Pharmaceutical industry, Neuron

Deploying high-resolution structures and sophisticated mechanistic models, our scientific team at Nura Bio has validated a conserved, NAD-dependent mechanism of inhibition of NAD hydrolases like SARM1 and CD38 as a viable therapeutic strategy for neuroprotection, said Shilpa Sambashivan, PhD, lead author and Chief Scientific Officer at Nura Bio.

Key Points: 
  • Deploying high-resolution structures and sophisticated mechanistic models, our scientific team at Nura Bio has validated a conserved, NAD-dependent mechanism of inhibition of NAD hydrolases like SARM1 and CD38 as a viable therapeutic strategy for neuroprotection, said Shilpa Sambashivan, PhD, lead author and Chief Scientific Officer at Nura Bio.
  • Since its conception in 2018, Nura Bio has been steadily growing a differentiated, small molecule pipeline focused on targets implicated in driving axon degeneration and neuroinflammation in neurological diseases.
  • Nura Bios lead program, the SARM1 inhibitor program is currently in IND-enabling studies with the goal of entering First-in-Human trials in early 2023.
  • At Nura Bio we envision a world where the diagnosis of a neurological disorder comes with the hope of a cure.